rheumatoid arthritis
GSK, Janssen RA treatment meets co-primary endpoints in Phase III trial
June 9, 2016Research and Development GSK, Janssen, eular 2016, rheumatoid arthritis, sirukumab
GSK (LSE: GSK) and Janssen, a division of Johnson and Johnson, have announced data from a pivotal Phase III study …
Samsung Bioepis takes AbbVie to court over attempts to delay Humira biosimilars
April 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing AbbVie, Biogen, Humira, Samsung Bioepis, biosimilars, rheumatoid arthritis
Samsung Bioepis has filed a lawsuit against Abbvie (NYSE: ABBV) to stop the maker of the world’s bestselling drug Humira …
Lilly’s RA drug baricitinib meets Phase III goals
March 31, 2016Research and Development Eli Lilly, Incyte, rheumatoid arthritis
Eli Lilly and Incyte have announced the publication of detailed Phase III trial results from a study of their biologic …
EMA to review Pfizer’s Xeljanz for patients with rheumatoid arthritis
March 24, 2016Research and Development, Sales and Marketing EMA, Pfizer, Xeljanz, approval, authorisation, marketing, review, rheumatoid arthritis
Pfizer (NYSE: PFE) has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application (MAA) …
Bristol-Myers Squibb to acquire Padlock Therapeutics for up to $600m
March 23, 2016Research and Development, Sales and Marketing Bristol-Myers Squibb, Padlock Therapeutics, rheumatoid arthritis
Bristol-Myers Squibb is to acquire Massachusetts-based auto-immune disease specialist Padlock Therapeutics in a deal worth up to $600 million. The …
Merck & Co says study shows significantly higher persistence for its arthritis drug Simponi
March 17, 2016Research and Development, Sales and Marketing Merck & Co, drug trial, research, rheumatoid arthritis
US pharma giant Merck & Co (NYSE: MRK) said its rheumatoid arthritis drug showed significantly higher persistence compared with other drugs …
First Enbrel biosimilar launches in UK
February 16, 2016Manufacturing and Production, Research and Development Enbrel, Samsung Bioepis, eternacept, rheumatoid arthritis
Following its approval by the European Commission in January, Benepali has become the first biosimilar of Pfizer/Amgen’s Enbrel (etanercept) to …
NICE backs biosimilars with arthritis drug endorsements
January 27, 2016Research and Development, Sales and Marketing DMARDs, NICE, biosimilars, rheumatoid arthritis
NICE has published updated final guidance recommending seven biological disease modifying drugs (DMARDs) for treatment of severe rheumatoid arthritis which …
Lilly awaits FDA review of new arthritis treatment
January 20, 2016Manufacturing and Production, Research and Development, Sales and Marketing Eli Lilly, FDA, Incyte, NDA, baricitinib, lilly, new drug application, rheumatoid arthritis
Eli Lilly has submitted a new drug application (NDA) to the FDA for baricitinib as a treatment for moderate-to-severe rheumatoid …
Baxalta’s Enbrel biosimilar measures up in late-stage study
January 13, 2016Research and Development Amgen, Baxalta, Enbrel, Pfizer, biosimilar, etanercept, rheumatoid arthritis
Having emerged from its mega-merger deal with Shire, Baxalta is back on its drug development day job – and has …
AbbVie begins late stage trials of rheumatoid arthritis drug
January 11, 2016Manufacturing and Production, Research and Development, Sales and Marketing ABT-494, AbbVie, F-star, JAK-1 inhibitor, rheumatoid arthritis
AbbVie has begun a large phase III clinical trial programme for its next-generation rheumatoid arthritis (RA) treatment ABT-494, which the …
FDA review for Sanofi and Regeneron’s biologic arthritis drug
January 8, 2016Medical Communications, Sales and Marketing FDA, Regeneron, Sanofi, biologics, rheumatoid arthritis, sarilumab
The FDA has accepted for review a Biologics License Application (BLA) from Sanofi and Regeneron for the rheumatoid arthritis treatment …
Gilead steps in to rescue Galapagos RA drug
December 18, 2015Sales and Marketing AbbVie, Gilead, Gilead Sciences, filgotinib, inflammation, inflammatory diseases, rheumatoid arthritis
Gilead Sciences is to pay $725million for the rights to filgotinib, a JAK1-selective inhibitor for rheumatoid arthritis and other inflammatory …
Lilly/Incyte RA drug bests Humira in Phase III trial
November 10, 2015Research and Development Humira, baricitinib, lilly, phase III, rheumatoid arthritis
Eli Lilly says its investigational therapy baricitinib outperformed AbbVie’s Humira after 12 weeks in a late-stage study of people with …
Sanofi’s rheumatoid arthritis biologic performs
May 22, 2015Sales and Marketing Sanofi, rheumatoid arthritis, sarilumab
French pharma giant Sanofi plans to submit its new rheumatoid arthritis biologic for regulatory approval in the US after it …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
